1. Home
  2. SEE vs CRSP Comparison

SEE vs CRSP Comparison

Compare SEE & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sealed Air Corporation

SEE

Sealed Air Corporation

HOLD

Current Price

$42.05

Market Cap

5.1B

Sector

Industrials

ML Signal

HOLD

Logo CRISPR Therapeutics AG

CRSP

CRISPR Therapeutics AG

HOLD

Current Price

$58.13

Market Cap

5.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SEE
CRSP
Founded
1960
2013
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.1B
5.6B
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
SEE
CRSP
Price
$42.05
$58.13
Analyst Decision
Strong Buy
Buy
Analyst Count
11
19
Target Price
$43.45
$71.50
AVG Volume (30 Days)
3.4M
2.5M
Earning Date
11-04-2025
11-10-2025
Dividend Yield
1.89%
N/A
EPS Growth
13.73
N/A
EPS
3.09
N/A
Revenue
$5,331,600,000.00
$38,337,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$1.16
$723.84
P/E Ratio
$13.67
N/A
Revenue Growth
N/A
N/A
52 Week Low
$22.78
$30.04
52 Week High
$44.27
$78.48

Technical Indicators

Market Signals
Indicator
SEE
CRSP
Relative Strength Index (RSI) 60.99 55.81
Support Level $42.44 $51.16
Resistance Level $43.27 $59.77
Average True Range (ATR) 0.65 3.19
MACD -0.26 1.15
Stochastic Oscillator 11.73 90.72

Price Performance

Historical Comparison
SEE
CRSP

About SEE Sealed Air Corporation

Sealed Air is organized via two reporting segments. Food includes food packaging products like Cryovac, Darfresh, and OptiDure aimed primarily at meats. Protective includes Sealed Air's Bubble Wrap, Instapak, Jiffy mailers, and shrink film packaging systems that cater to industrial and e-commerce applications.

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Share on Social Networks: